Answers are grounded in this paper and cite their sources.
Reacquiring the target: A proteomic profiling approach has been used to show that aldehyde dehydrogenase 1 may be an additional or alternative target of duocarmycin. Selective inhibition of this enzyme in lung cancer cells explains the antitumor activity of duocarmycin analogues (see scheme).
No takes yet. Share an insight, caveat, or question.
Wirth et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: